

Ran Reshef

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8227679/publications.pdf>

Version: 2024-02-01

152
papers

4,375
citations

126907

33
h-index

123424

61
g-index

154
all docs

154
docs citations

154
times ranked

6090
citing authors

#	ARTICLE	IF	CITATIONS
1	Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and <i>KMT2A</i> -rearranged AML. <i>Blood Advances</i> , 2022, 6, 828-847.	5.2	5
2	Antibiotic Exposure, Not Alloreactivity, Is the Major Driver of Microbiome Changes in Hematopoietic Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 135-144.	1.2	11
3	Assessment of systemic and gastrointestinal tissue damage biomarkers for GVHD risk stratification. <i>Blood Advances</i> , 2022, 6, 3707-3715.	5.2	9
4	Baloxavir treatment of oseltamivir-resistant influenza A/H1pdm09 in two immunocompromised patients. <i>Transplant Infectious Disease</i> , 2021, 23, e13542.	1.7	9
5	Rewiring the CAR "Combination strategies to enhance CAR T cell effectiveness. <i>Blood Reviews</i> , 2021, 45, 100695.	5.7	22
6	Extended letermovir administration, beyond day 100, is effective for CMV prophylaxis in patients with graft versus host disease. <i>Transplant Infectious Disease</i> , 2021, 23, e13487.	1.7	14
7	Standardized Semistructured Psychosocial Evaluation Before Stem Cell Transplantation Predicts Delirium After Transplant. <i>Journal of the Academy of Consultation-Liaison Psychiatry</i> , 2021, 62, 440-444.	0.4	3
8	Gastrointestinal toxicity of high-dose melphalan in autologous hematopoietic stem cell transplantation: identification of risk factors and a benchmark for experimental therapies. <i>Annals of Hematology</i> , 2021, 100, 1863-1870.	1.8	11
9	Peripheral blood stem cell grafts in allogeneic hematopoietic cell transplantation: It is not all about the CD34+ cell dose. <i>Transfusion and Apheresis Science</i> , 2021, 60, 103081.	1.0	1
10	Variable selection methods for predicting clinical outcomes following allogeneic hematopoietic cell transplantation. <i>Scientific Reports</i> , 2021, 11, 3230.	3.3	1
11	What about tocilizumab? A retrospective study from a NYC Hospital during the COVID-19 outbreak. <i>PLoS ONE</i> , 2021, 16, e0249349.	2.5	12
12	HLA Haploidentical versus Matched Unrelated Donor Transplants with Post-Transplant Cyclophosphamide based prophylaxis. <i>Blood</i> , 2021, 138, 273-282.	1.4	88
13	Current and Future Role of Medical Imaging in Guiding the Management of Patients With Relapsed and Refractory Non-Hodgkin Lymphoma Treated With CAR T-Cell Therapy. <i>Frontiers in Oncology</i> , 2021, 11, 664688.	2.8	10
14	Preliminary safety and efficacy of PBCAR0191, an allogeneic, off-the-shelf CD19-targeting CAR-T product, in relapsed/refractory (r/r) CD19+ NHL. <i>Journal of Clinical Oncology</i> , 2021, 39, 7516-7516.	1.6	17
15	TGM4: an immunogenic prostate-restricted antigen. , 2021, 9, e001649.		11
16	Acute GVHD Diagnosis and Adjudication in a Multicenter Trial: A Report From the BMT CTN 1202 Biorepository Study. <i>Journal of Clinical Oncology</i> , 2021, 39, 1878-1887.	1.6	14
17	Cellular Immunotherapy"Highlights from TCT 2021. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 527-532.	1.2	2
18	Impact of Previously Unrecognized HLA Mismatches Using Ultrahigh Resolution Typing in Unrelated Donor Hematopoietic Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2021, 39, 2397-2409.	1.6	19

#	ARTICLE	IF	CITATIONS
19	Fludarabine and Melphalan Compared with Reduced Doses of Busulfan and Fludarabine Improve Transplantation Outcomes in Older Patients with Myelodysplastic Syndromes. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 921.e1-921.e10.	1.2	11
20	Evaluation of Elafin as a Prognostic Biomarker in Acute Graft-versus-Host Disease. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 988.e1-988.e7.	1.2	10
21	Vitamin D deficiency after allogeneic hematopoietic cell transplantation promotes T-cell activation and is inversely associated with an EZH2-ID3 signature. <i>Transplantation and Cellular Therapy</i> , 2021, 28, 18.e1-18.e1.	1.2	4
22	Impact of Molecular Features of Diffuse Large B-Cell Lymphoma on Treatment Outcomes with Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy. <i>Blood</i> , 2021, 138, 165-165.	1.4	6
23	Long-Term Follow-up Analysis of ZUMA-5: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL). <i>Blood</i> , 2021, 138, 93-93.	1.4	12
24	Multicenter, Open-Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Recipients with Epstein-Barr Virus-Driven Post Transplant Lymphoproliferative Disease after Failure of Rituximab or Rituximab and Chemotherapy (ALLELE). <i>Blood</i> , 2021, 138, 301-301.	1.4	6
25	Prognostic Value of Elafin in Acute Graft-Versus-Host Disease. <i>Blood</i> , 2021, 138, 3900-3900.	1.4	0
26	Allogeneic CAR-T PBCAR0191 with Intensified Lymphodepletion Is Highly Active in Patients with Relapsed/Refractory B-Cell Malignancies. <i>Blood</i> , 2021, 138, 302-302.	1.4	16
27	Impact of Allogeneic Hematopoietic Cell Transplantation (HCT) As Consolidation Following CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy for Treatment of Relapsed Acute Lymphoblastic Leukemia (ALL). <i>Blood</i> , 2021, 138, 3880-3880.	1.4	4
28	Chimeric antigen receptor T cells for treatment of transformed Waldenström macroglobulinemia. <i>Leukemia and Lymphoma</i> , 2020, 61, 465-468.	1.3	13
29	Maintenance Tyrosine Kinase Inhibitors Following Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Myelogenous Leukemia: A Center for International Blood and Marrow Transplant Research Study. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 472-479.	2.0	21
30	COVID-19 Infections and Clinical Outcomes in Patients with Multiple Myeloma in New York City: A Cohort Study from Five Academic Centers. <i>Blood Cancer Discovery</i> , 2020, 1, 234-243.	5.0	46
31	Fertility Concerns and Access to Care for Stem Cell Transplantation Candidates with Sickle Cell Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, e192-e197.	2.0	17
32	Disease risk and GVHD biomarkers can stratify patients for risk of relapse and nonrelapse mortality post hematopoietic cell transplant. <i>Leukemia</i> , 2020, 34, 1898-1906.	7.2	16
33	Long-Term Outcomes of Patients with Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease Following Solid Organ Transplant or Allogeneic Hematopoietic Cell Transplant Treated with Tabelecleucel in a Multicenter Expanded Access Program Study. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, S61-S62.	2.0	3
34	ZUMA-19: A Phase 1/2 Multicenter Study of Lenzilumab Use With Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) With Relapsed or Refractory Large B Cell Lymphoma (R/R LBCL). <i>Blood</i> , 2020, 136, 6-7.	1.4	8
35	Biomarker-guided preemption of steroid-refractory graft-versus-host disease with Î±-1-antitrypsin. <i>Blood Advances</i> , 2020, 4, 6098-6105.	5.2	24
36	168â€¦A novel prostate-restricted tumor-associated antigen: a potential therapeutic target. , 2020, , .		0

#	ARTICLE	IF	CITATIONS
37	Clinical Experience of Tabelecleucel in Patients with Life-Threatening Complications of Epstein-Barr Virus Viremia. <i>Blood</i> , 2020, 136, 7-8.	1.4	0
38	Comparison of Outcomes after Haploidentical Relative and HLA Matched Unrelated Donor Transplantation with Post-Transplant Cyclophosphamide Containing Gvhd Prophylaxis Regimens. <i>Blood</i> , 2020, 136, 21-22.	1.4	0
39	Glucagon-like Peptide-2 (GLP-2) Treatment Reduces Gvhd-Related Mortality in a Pre-Clinical Transplant Model Via Expansion of Macrophages with Tolerogenic Potential. <i>Blood</i> , 2020, 136, 26-28.	1.4	0
40	Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocytic Leukemia Patients: Center for International Blood and Marrow Transplant Research Report. <i>Clinical Cancer Research</i> , 2019, 25, 5143-5155.	7.0	10
41	Standardized Semi-structured Psychosocial Evaluation before Hematopoietic Stem Cell Transplantation Predicts Patient Adherence to Post-Transplant Regimen. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2222-2227.	2.0	24
42	Impact of T Cell Dose on Outcome of T Cell-Replete HLA-Matched Allogeneic Peripheral Blood Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1875-1883.	2.0	14
43	Acute Gvhd Diagnosis and Adjudication in a Multicenter Trial – a Report from the BMT CTN 1202 Biorepository Study. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, S54.	2.0	0
44	Diagnosis of Light Chain Amyloidosis Is the Primary Risk Factor for Engraftment Syndrome after Autologous Stem Cell Transplant in a Contemporary Cohort. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, S393-S394.	2.0	0
45	Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203). <i>Lancet Haematology</i> , 2019, 6, e132-e143.	4.6	200
46	Comparison of Gvhd Biomarker Algorithms for Predicting Lethal Gvhd and Non-Relapse Mortality. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, S53-S54.	2.0	3
47	The MAGIC algorithm probability is a validated response biomarker of treatment of acute graft-versus-host disease. <i>Blood Advances</i> , 2019, 3, 4034-4042.	5.2	63
48	Effect of Conditioning Regimen Dose Reduction in Obese Patients Undergoing Autologous Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 480-487.	2.0	10
49	Extended CCR5 Blockade for Graft-versus-Host Disease Prophylaxis Improves Outcomes of Reduced-Intensity Unrelated Donor Hematopoietic Cell Transplantation: A Phase II Clinical Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 515-521.	2.0	24
50	ZUMA-11: A Phase 1/2 Multicenter Study of Axicabtagene Ciloleucel (Axi-Cel) + Utomilumab Patients with Refractory Large B Cell Lymphoma. <i>Blood</i> , 2019, 134, 4084-4084.	1.4	5
51	Long-Term Outcomes of Subjects with Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disorder (EBV+PTLD) Following Solid Organ (SOT) or Allogeneic Hematopoietic Cell Transplants (HCT) Treated with Tabelecleucel on an Expanded Access Program. <i>Blood</i> , 2019, 134, 4071-4071.	1.4	6
52	A Phase 2, Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Axicabtagene Ciloleucel in Combination with Either Rituximab or Lenalidomide in Patients with Refractory Large B-Cell Lymphoma (ZUMA-14). <i>Blood</i> , 2019, 134, 4093-4093.	1.4	8
53	Autologous Transplant Recipients Have a Healthier Gut Microbiota at Baseline and Faster Recovery from Microbiome Injury Compared to Allogeneic Transplant Recipients. <i>Blood</i> , 2019, 134, 4491-4491.	1.4	0
54	The MAGIC Algorithm Probability (MAP): A Novel Laboratory Biomarker for the Response to Treatment of Acute Graft-Versus-Host Disease. <i>Blood</i> , 2019, 134, 367-367.	1.4	0

#	ARTICLE	IF	CITATIONS
55	Excellent Survival and Immune Reconstitution Following Matched/Mismatched Unrelated and Mismatched Related Transplantation in Adult Patients with Sickle Cell Disease: Updated Results from a Single Center Experience. <i>Blood</i> , 2019, 134, 2043-2043.	1.4	0
56	Efficacy and Safety of ATA129, Partially Matched Allogeneic Third-Party Epstein-Barr Virus-Targeted Cytotoxic T Lymphocytes in a Multicenter Study for Post-Transplant Lymphoproliferative Disorder. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, S41-S42.	2.0	6
57	Gastrointestinal Toxicity of High-Dose Melphalan in Autologous Stem-Cell Transplantation: Identification of Risk Factors and a Benchmark for Experimental Therapies. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, S130.	2.0	2
58	The changing face of adult posttransplant lymphoproliferative disorder: Changes in histology between 1999 and 2013. <i>American Journal of Hematology</i> , 2018, 93, 874-881.	4.1	7
59	Donor body mass index does not predict graft versus host disease following hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2018, 53, 932-937.	2.4	1
60	Blood and Marrow Transplant Clinical Trials Network Report on the Development of Novel Endpoints and Selection of Promising Approaches for Graft-versus-Host Disease Prevention Trials. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1274-1280.	2.0	46
61	MAGIC biomarkers predict long-term outcomes for steroid-resistant acute GVHD. <i>Blood</i> , 2018, 131, 2846-2855.	1.4	140
62	Pharmacodynamic Monitoring Predicts Outcomes of CCR5 Blockade as Graft-versus-Host Disease Prophylaxis. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 594-599.	2.0	6
63	Effect of donor characteristics on haploidentical transplantation with posttransplantation cyclophosphamide. <i>Blood Advances</i> , 2018, 2, 299-307.	5.2	69
64	Higher Donor Apheresis Blood Volumes Are Associated with Reduced Relapse Risk and Improved Survival in Reduced-Intensity Allogeneic Transplantations with Unrelated Donors. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1203-1208.	2.0	1
65	Upper gastrointestinal acute graft-versus-host disease adds minimal prognostic value in isolation or with other graft-versus-host disease symptoms as currently diagnosed and treated. <i>Haematologica</i> , 2018, 103, 1708-1719.	3.5	8
66	Iatrogenic Infertility After Curative Stem Cell Transplantation in Patients With Sickle Cell Disease. <i>Annals of Internal Medicine</i> , 2018, 168, 881.	3.9	8
67	Serial Biomarker Monitoring Early after HCT Identifies Different Risks for Relapse and Graft-Vs-Host Disease. <i>Blood</i> , 2018, 132, 356-356.	1.4	0
68	Stim1 Deletion Synthetically Rescues Ezh2-Null Effector T Cells and Alloimmunity. <i>Blood</i> , 2018, 132, 4533-4533.	1.4	0
69	Curative Allogeneic Stem Cell Transplantation Is Safe and Feasible in Adult Patients with Sickle Cell Disease Despite Lack of Matched Sibling Donor and Presence of Sickle Cell-Related Co-Morbidities. <i>Blood</i> , 2018, 132, 5713-5713.	1.4	0
70	Clinical and immunologic impact of CCR5 blockade in graft-versus-host disease prophylaxis. <i>Blood</i> , 2017, 129, 906-916.	1.4	56
71	Allogeneic Hematopoietic Cell Transplantation for Adult Chronic Myelomonocytic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 767-775.	2.0	41
72	Extended Course of Maraviroc, a CCR5 Antagonist, Is Safe and Effective in Graft-Versus-Host Disease Prophylaxis. Final Results of a Phase II Study. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1-3.	2.0	1

#	ARTICLE	IF	CITATIONS
73	Hsp90 inhibition destabilizes Ezh2 protein in alloreactive T cells and reduces graft-versus-host disease in mice. <i>Blood</i> , 2017, 129, 2737-2748.	1.4	31
74	GvHD after umbilical cord blood transplantation for acute leukemia: an analysis of risk factors and effect on outcomes. <i>Bone Marrow Transplantation</i> , 2017, 52, 400-408.	2.4	42
75	Posttransplant Lymphoproliferative Disorder in Solid Organ and Hematopoietic Stem Cell Transplantation. <i>Clinics in Chest Medicine</i> , 2017, 38, 771-783.	2.1	14
76	Ezh2 phosphorylation state determines its capacity to maintain CD8+ T memory precursors for antitumor immunity. <i>Nature Communications</i> , 2017, 8, 2125.	12.8	99
77	Long-term outcomes of rituximab, temozolomide and high-dose methotrexate without consolidation therapy for lymphoma involving the CNS. <i>International Journal of Hematologic Oncology</i> , 2017, 6, 113-121.	1.6	15
78	An early-biomarker algorithm predicts lethal graft-versus-host disease and survival. <i>JCI Insight</i> , 2017, 2, e89798.	5.0	166
79	Prospective, Randomized, Double-Blind, Phase III Clinical Trial of Anti-CD25 Inhibitor to Assess Impact on Chronic Graft-Versus-Host Disease-Free Survival in Patients Undergoing HLA-Matched Unrelated Myeloablative Hematopoietic Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2017, 35, 4003-4011.	1.6	258
80	Antifibrotic Effects of the Dual CCR2/CCR5 Antagonist Cenicriviroc in Animal Models of Liver and Kidney Fibrosis. <i>PLoS ONE</i> , 2016, 11, e0158156.	2.5	258
81	Infusion of CD3/CD28 costimulated umbilical cord blood T cells at the time of single umbilical cord blood transplantation may enhance engraftment. <i>American Journal of Hematology</i> , 2016, 91, 453-460.	4.1	7
82	Unrelated donors are associated with improved relapse-free survival compared to related donors in patients with myelodysplastic syndrome undergoing reduced intensity allogeneic stem cell transplantation. <i>American Journal of Hematology</i> , 2016, 91, 883-887.	4.1	3
83	Does FLT3 mutation impact survival after hematopoietic stem cell transplantation for acute myeloid leukemia? A Center for International Blood and Marrow Transplant Research (CIBMTR) analysis. <i>Cancer</i> , 2016, 122, 3005-3014.	4.1	45
84	Scoring System Prognostic of Outcome in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome. <i>Journal of Clinical Oncology</i> , 2016, 34, 1864-1871.	1.6	61
85	Programming of donor T cells using allogeneic CD28-like ligand-expressing dendritic cells to reduce GVHD in mice. <i>Blood</i> , 2016, 127, 3270-3280.	1.4	22
86	Clinical Utility of Next-Generation Sequencing for Oncogenic Mutations in Patients with Acute Myeloid Leukemia Undergoing Allogeneic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1961-1967.	2.0	30
87	Human leukocyte antigen supertype matching after myeloablative hematopoietic cell transplantation with 7/8 matched unrelated donor allografts: a report from the Center for International Blood and Marrow Transplant Research. <i>Haematologica</i> , 2016, 101, 1267-1274.	3.5	22
88	Shaping the Molecular Landscape of Posttransplantation Lymphoproliferative Disorders. <i>American Journal of Transplantation</i> , 2016, 16, 379-380.	4.7	2
89	Precision in donor selection: Identifying ideal stem-cell donors through their TCRs. <i>Experimental Hematology</i> , 2016, 44, 1020-1023.	0.4	11
90	Time to unrelated donor leukocyte infusion is longer, but incidence of GVHD and overall survival are similar for recipients of unrelated DLI compared to matched sibling DLI. <i>American Journal of Hematology</i> , 2016, 91, 426-429.	4.1	3

#	ARTICLE	IF	CITATIONS
91	Higher Apheresis Blood Volumes Are Associated with a Reduction in Relapse Risk and Improved Survival in Patients Undergoing Reduced Intensity Allogeneic Transplants from Unrelated Donors, Potentially Due to Higher CD8 T-Cell Doses. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, S311-S312.	2.0	0
92	Hematopoietic Cell Transplantation Outcomes in Monosomal Karyotype Myeloid Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 248-257.	2.0	33
93	Higher tacrolimus concentrations early after transplant reduce the risk of acute GvHD in reduced-intensity allogeneic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2016, 51, 568-572.	2.4	36
94	The Notch Ligand DLL4 Defines a Capability of Human Dendritic Cells in Regulating Th1 and Th17 Differentiation. <i>Journal of Immunology</i> , 2016, 196, 1070-1080.	0.8	53
95	International, Multicenter Standardization of Acute Graft-versus-Host Disease Clinical Data Collection: A Report from the Mount Sinai Acute GVHD International Consortium. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 4-10.	2.0	487
96	A Prospective Randomized Double Blind Phase 3 Clinical Trial of Anti-T Lymphocyte Globulin (ATLG) to Assess Impact on Chronic Graft-Versus-Host Disease (cGVHD) Free Survival in Patients Undergoing HLA Matched Unrelated Myeloablative Hematopoietic Cell Transplantation (HCT). <i>Blood</i> , 2016, 128, 505-505.	1.4	12
97	An Early Biomarker Algorithm Predicts Lethal Graft-Versus-Host Disease and Survival after Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , 2016, 128, 509-509.	1.4	1
98	Biomarkers Predict Graft-Vs-Host Disease Outcomes Better Than Clinical Response after One Week of Treatment. <i>Blood</i> , 2016, 128, 510-510.	1.4	0
99	NKG2D expression by CD8+ T cells contributes to GVHD and GVT effects in a murine model of allogeneic HSCT. <i>Blood</i> , 2015, 125, 3655-3663.	1.4	40
100	Pharmacodynamic Assessment Shows That CCR5 Surface Expression May Serve As an Indicator for Effective CCR5 Blockade in Allogeneic Stem Cell Transplant (alloSCT) Recipients Treated with Maraviroc. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, S332-S333.	2.0	0
101	The Impact of EBV Status on Characteristics and Outcomes of Posttransplantation Lymphoproliferative Disorder. <i>American Journal of Transplantation</i> , 2015, 15, 2665-2673.	4.7	137
102	Reduced-intensity conditioned allogeneic SCT in adults with AML. <i>Bone Marrow Transplantation</i> , 2015, 50, 759-769.	2.4	34
103	Allogeneic hematopoietic cell transplant for AML: no impact of pre-transplant extramedullary disease on outcome. <i>Bone Marrow Transplantation</i> , 2015, 50, 1057-1062.	2.4	23
104	Tacrolimus versus Cyclosporine after Hematopoietic Cell Transplantation for Acquired Aplastic Anemia. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1776-1782.	2.0	13
105	High Graft CD8 Cell Dose Predicts Improved Survival and Enables Better Donor Selection in Allogeneic Stem-Cell Transplantation With Reduced-Intensity Conditioning. <i>Journal of Clinical Oncology</i> , 2015, 33, 2392-2398.	1.6	52
106	A Survival Benefit for Reduced Intensity Allogeneic Transplants from Young Unrelated Donors Compared to Older Sibling Donors Depends on the Graft CD8 T-Cell Content. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, S42-S43.	2.0	1
107	The Impact of Graft-versus-Host Disease on the Relapse Rate in Patients with Lymphoma Depends on the Histological Subtype and the Intensity of the Conditioning Regimen. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1746-1753.	2.0	48
108	Acute Cholecystitis Is a Common Complication after Allogeneic Stem Cell Transplantation and Is Associated with the Use of Total Parenteral Nutrition. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 768-771.	2.0	7

#	ARTICLE	IF	CITATIONS
109	Lack of a significant pharmacokinetic interaction between maraviroc and tacrolimus in allogeneic HSCT recipients. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 2078-2083.	3.0	4
110	Immunologic Effects of CCR5 Blockade in Graft-Versus-Host Disease Prophylaxis. <i>Blood</i> , 2015, 126, 920-920.	1.4	1
111	Guidelines for the Standardization of Acute Graft-Versus-Host Disease Clinical Data Collection: An International Consensus Report. <i>Blood</i> , 2015, 126, 3154-3154.	1.4	0
112	Unrelated Donors Are Associated with Improved Relapse Free Survival Compared to Related Donors in Patients with Myelodysplastic Syndrome Undergoing Reduced Intensity Conditioned Allogeneic Stem-Cell Transplantation. <i>Blood</i> , 2015, 126, 4380-4380.	1.4	0
113	The Notch Ligand DLL4 Derived from Human Dendritic Cells Is Critical for Promoting T Helper (Th)1 and Th17 Cell Differentiation. <i>Blood</i> , 2015, 126, 3431-3431.	1.4	0
114	Programming of Donor T Cells Using Allogeneic Delta-like Ligand 4-Positive Dendritic Cells to Reduce Gvhd but Retain GVL Activity. <i>Blood</i> , 2015, 126, 233-233.	1.4	25
115	Pharmacological Inhibition of Hsp90 Destabilizes the Histone Methyltransferase Ezh2 in Alloreactive T Cells and Reduces Graft-Versus-Host Disease While Retaining Anti-Leukemic Effects in Mice. <i>Blood</i> , 2015, 126, 234-234.	1.4	0
116	Improved accuracy of acute graft-versus-host disease staging among multiple centers. <i>Best Practice and Research in Clinical Haematology</i> , 2014, 27, 283-287.	1.7	23
117	Early Donor Chimerism Levels Predict Relapse and Survival after Allogeneic Stem Cell Transplantation with Reduced-Intensity Conditioning. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1758-1766.	2.0	52
118	High CD8 Cell Doses Correlate with Reduced Relapse Risk and Improved Survival after Allogeneic Peripheral Blood Stem-Cell Transplantation with Reduced-Intensity Conditioning. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, S249.	2.0	0
119	An Evaluation of a Pharmacokinetic Interaction Between Tacrolimus and Maraviroc in Allogeneic Stem Cell Transplant Recipients. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, S289.	2.0	0
120	Clofarabine Busulfan Conditioning Improves Outcomes in Patients with Active Acute Myelogenous Leukemia Undergoing Allogeneic Stem Cell Transplant. <i>Blood</i> , 2014, 124, 1239-1239.	1.4	4
121	CD8 Cell Dose in Peripheral Blood Stem-Cell Grafts Correlates with Relapse and Survival after Reduced Intensity Allogeneic Stem-Cell Transplantation. <i>Blood</i> , 2014, 124, 1260-1260.	1.4	1
122	Extended CCR5 Blockade in Graft-Versus-Host Disease Prophylaxis – a Phase II Study. <i>Blood</i> , 2014, 124, 2491-2491.	1.4	4
123	Next-generation sequencing to identify mutations that may predict outcome after allogeneic stem cell transplantation for AML. <i>Journal of Clinical Oncology</i> , 2014, 32, 7043-7043.	1.6	1
124	Time from Relapse to Donor Leukocyte Infusion in Allogeneic Stem Cell Transplantation Patients Is Longer for Recipients of Unrelated DLI Compared to Matched Sibling DLI, with Similar Incidence of Graft Versus Host Disease (GVHD) and Survival. <i>Blood</i> , 2014, 124, 3946-3946.	1.4	0
125	Pilot Study of Prophylactic Ex Vivo Costimulated Donor Leukocyte Infusion After Reduced-Intensity Conditioned Allogeneic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1094-1101.	2.0	26
126	Plasmacytic post-transplant lymphoproliferative disorder: a case series of nine patients. <i>Transplant International</i> , 2013, 26, 616-622.	1.6	40

#	ARTICLE	IF	CITATIONS
127	EBV-negative post-transplant lymphoproliferative disorder: Clinical characteristics, response to therapy, and survival.. Journal of Clinical Oncology, 2013, 31, 8578-8578.	1.6	1
128	Acute Cholecystitis Occurs More Commonly Than Expected Following Allogeneic Hematopoietic Stem Cell Transplantation and Is Ineffectively Diagnosed Using Abdominal Ultrasound. Blood, 2013, 122, 2046-2046.	1.4	0
129	High-dose corticosteroids with or without etanercept for the treatment of idiopathic pneumonia syndrome after allo-SCT. Bone Marrow Transplantation, 2012, 47, 1332-1337.	2.4	55
130	Blockade of Lymphocyte Chemotaxis in Visceral Graft-versus-Host Disease. New England Journal of Medicine, 2012, 367, 135-145.	27.0	235
131	Post-transplant lymphoproliferative disorder after lung transplantation: A review of 35 cases. Journal of Heart and Lung Transplantation, 2012, 31, 296-304.	0.6	52
132	Costimulated tumor-infiltrating lymphocytes are a feasible and safe alternative donor cell therapy for relapse after allogeneic stem cell transplantation. Blood, 2012, 119, 2956-2959.	1.4	17
133	Prevention of graft-versus-host disease. Clinical Advances in Hematology and Oncology, 2012, 10, 663-5.	0.3	3
134	Reduction of Immunosuppression as Initial Therapy for Posttransplantation Lymphoproliferative Disorderâ.... American Journal of Transplantation, 2011, 11, 336-347.	4.7	185
135	Association of HLA Polymorphisms with Post-transplant Lymphoproliferative Disorder in Solid-Organ Transplant Recipients. American Journal of Transplantation, 2011, 11, 817-825.	4.7	47
136	Inflammatory cytokine inhibition with combination daclizumab and infliximab for steroid-refractory acute GVHD. Bone Marrow Transplantation, 2011, 46, 430-435.	2.4	32
137	Inhibition of Lymphocyte Trafficking Using a CCR5 Antagonist â Final Results of a Phase I/II Study. Blood, 2011, 118, 1011-1011.	1.4	2
138	Posttransplant Lymphoproliferative Disorder in Kidney Transplant Patients: A Report of 68 Cases. Blood, 2011, 118, 2662-2662.	1.4	0
139	Whole Blood Donor Chimerism At Day 30 After Reduced Intensity Conditioned Allogeneic Stem-Cell Transplantation Predicts Disease Relapse, and Is Strongly Associated with Pretransplant Lymphodepletion. Blood, 2011, 118, 1939-1939.	1.4	0
140	A Phase 1 Dose Escalation Study of Infusion of Ex Vivo CD3/CD28 Costimulated Umbilical Cord Blood-Derived T Cells in Adults Undergoing Transplantation for Advanced Hematologic Malignancies. Blood, 2011, 118, 3032-3032.	1.4	0
141	Posttransplant Lymphoproliferative Disorder Following Kidney Transplant. American Journal of Kidney Diseases, 2010, 55, 168-180.	1.9	28
142	Prevention of Graft-Versus-Host Disease by Inhibition of Lymphocyte Trafficking Using a CCR5 Antagonist. Blood, 2010, 116, 673-673.	1.4	2
143	Outcomes of Myeloablative Hematopoietic Stem Cell Transplantation for Patients with Acute Myelogenous Leukemia with Relapsed or Refractory Disease. Blood, 2010, 116, 2366-2366.	1.4	0
144	Reduced Intensity Conditioning with Fludarabine/Busulfan 6.4mg/Kg Results In High Donor Chimerism and Low Toxicity In Both Related and Unrelated Allo-SCT for Hematologic Malignancies.. Blood, 2010, 116, 4519-4519.	1.4	0

#	ARTICLE	IF	CITATIONS
145	Functional Unresponsiveness and Replicative Senescence of Myeloid Leukemia Antigen-specific CD8+ T Cells After Allogeneic Stem Cell Transplantation. <i>Clinical Cancer Research</i> , 2009, 15, 4944-4953.	7.0	51
146	Reduction of Immunosuppression as Initial Therapy for Post-Transplantation Lymphoproliferative Disorder: Analysis of Efficacy, Safety and Prognostic Factors.. <i>Blood</i> , 2009, 114, 103-103.	1.4	2
147	Combination Daclizumab and Infliximab for Steroid Refractory Acute Graft-Versus-Host Disease.. <i>Blood</i> , 2009, 114, 4643-4643.	1.4	0
148	Rituximab for PTLD of the CNS: Is It a "No-Brainer"? <i>Oncology Research and Treatment</i> , 2008, 31, 650-651.	1.2	4
149	EBV-Negative Post-Transplant Lymphoproliferative Disorder (PTLD): A Retrospective Case-Control Study of Clinical and Pathological Characteristics, Response to Treatment and Survival. <i>Blood</i> , 2008, 112, 2823-2823.	1.4	6
150	Arginine uptake is attenuated, through post-translational regulation of cationic amino acid transporter-1, in hyperlipidemic rats. <i>Atherosclerosis</i> , 2007, 194, 357-363.	0.8	26
151	Arginine uptake is attenuated through modulation of cationic amino-acid transporter-1, in uremic rats. <i>Kidney International</i> , 2006, 69, 298-303.	5.2	39
152	Differential regulation of L-arginine transporters (cationic amino acid transporter-1 and -2) by peroxynitrite in rat mesangial cells. <i>Nephrology Dialysis Transplantation</i> , 2006, 21, 3409-3414.	0.7	6